Contact

Email

mohammad.bazargan@unimelb.edu.au

Credentials

Position
Clinical (Associate Professor)
Department of Medicine
ORCID

0000-0001-6566-6215

Dr Ali Bazargan

Clinical (Associate Professor)
Department of Medicine
39 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Refractory coeliac disease or something else?
    DOI: 10.1016/j.pathol.2025.08.004
  • 2024

    Conference Proceedings

    A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis
    DOI: 10.1200/jco.2024.42.16_suppl.7056
  • 2023

    Journal article

    Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
    DOI: 10.1182/blood-2023-182019
  • 2023

    Journal article

    Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study
    DOI: 10.1182/blood-2023-182536
  • 2023

    Journal article

    P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
    DOI: 10.1097/01.hs9.0000971168.59900.67
  • 2023

    Journal article

    PREDICTORS OF NEW-ONSET, LONG-TERM ANTICOAGULANT USE AFTER HIP AND KNEE ARTHROPLASTY
    DOI: 10.1302/1358-992x.2023.3.086
  • 2022

    Conference Proceedings

    Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
    DOI: 10.1182/blood-2022-166670
Ali Bazargan

RECENT SCHOLARLY WORKS

  • 2022

    Journal article

    T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
    DOI: 10.1097/01.hs9.0000890800.36906.bb
  • 2022

    Journal article

    P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
    DOI: 10.1097/01.hs9.0000847216.85071.f3
  • 2022

    Conference Proceedings

    Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study
    DOI: 10.1200/jco.2022.40.16_suppl.7545